396 related articles for article (PubMed ID: 25197005)
1. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
2. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
Pascoe S; Wu W; Zhu CQ; Singh D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2035-40. PubMed ID: 27621609
[TBL] [Abstract][Full Text] [Related]
3. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
[TBL] [Abstract][Full Text] [Related]
4. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
5. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Norris V; Ambery C
Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of nebulized levalbuterol in stable COPD.
Datta D; Vitale A; Lahiri B; ZuWallack R
Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
[TBL] [Abstract][Full Text] [Related]
11. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
12. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
Colice GL
Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712
[TBL] [Abstract][Full Text] [Related]
13. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
Singh D; Abbott-Banner K; Bengtsson T; Newman K
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166326
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
16. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
[TBL] [Abstract][Full Text] [Related]
18. The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Respir Med; 2013 Sep; 107(9):1393-9. PubMed ID: 23768736
[TBL] [Abstract][Full Text] [Related]
19. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Campbell S
Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
[TBL] [Abstract][Full Text] [Related]
20. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.
Gross N; Tashkin D; Miller R; Oren J; Coleman W; Linberg S
Respiration; 1998; 65(5):354-62. PubMed ID: 9782217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]